enduriontx

TissueNav™ Platform

Computationally Guided Immune Cell Homing for Solid Tumour Infiltration

The Problem

CAR-T therapies have transformed outcomes in haematological malignancies — cancers of the blood and bone marrow. But in solid tumours, which represent the vast majority of cancer diagnoses, cell therapies have consistently underperformed. The reason is not a failure of cell engineering; it is a failure of cell delivery.

Solid tumours are surrounded by a hostile microenvironment that actively excludes immune cells. Even highly potent engineered T cells and NK cells struggle to reach, penetrate, and persist within these tissues. Until this barrier is addressed, the promise of cell therapy in solid tumours will remain largely unrealised.

Contact Us

Our Approach

TissueNav™ is a computational biology-driven platform that identifies the molecular signatures immune cells use to home to and infiltrate specific tissues — and then engineers those signatures into therapeutic cell products.

The platform mines large-scale, publicly available single-cell genomics and spatial transcriptomics datasets — including data from tumour-infiltrating lymphocyte populations — to decode the combinatorial surface codes that distinguish immune cells that successfully infiltrate tumours from those that do not. These are not single-receptor solutions; they are multi-factor molecular programmes identified through systematic computational analysis.

Once identified, these homing signatures are engineered into cytotoxic T cells, NK cells, or other immune effector populations using directed evolution approaches that iteratively optimise receptor combinations for specific tissue targets. The result is a cell therapy product designed not only to kill tumour cells, but to find them.
Contact Us

Key Platform Features

Data-Driven Discovery

Computational mining of single-cell and spatial transcriptomics datasets to identify non-obvious, combinatorial homing signatures — moving beyond single-receptor approaches to multi-factor surface codes.

Solid Tumour Focus

Directly engineered to address the tumour microenvironment exclusion problem — the primary reason cell therapies have failed to translate from blood cancers to solid malignancies.

Directed Evolution Optimisation

Iterative engineering and selection of receptor combinations fine-tuned for specific tissue targets, enabling progressive improvement of homing efficiency.

Multi-Cell-Type Versatility

The same homing engineering approach can be applied across T cells, NK cells, and macrophages — enabling indication-specific cell type selection without rebuilding the discovery platform.

Combination-Ready Architecture

Designed to layer onto existing cell therapy products, including Endurion's own SequencedCAR™ in-vivo CAR-T platform — creating a combined approach that both generates and directs engineered immune cells.

Clinical Potential & Pipeline Application

TissueNav™ is being developed to enhance the solid tumour activity of Endurion’s pipeline programmes and to serve as a licensable platform technology for external cell therapy developers. The platform’s tissue-specific homing signatures are designed to be modular — applicable across different CAR constructs, different cell types, and different tumour indications.
Initial development is focused on tumour types with well-characterised microenvironment barriers and high unmet clinical need. TissueNav™ represents Endurion’s strategy to extend the reach of cell therapy beyond the haematological indications where it has succeeded to date.
how we works

Our Working Proccess

Clients Projects

Lorem ipsum dolor sit amet consectetur.

General Proposal

Lorem ipsum dolor sit amet consectetur.

Testing Begins

Lorem ipsum dolor sit amet consectetur.

Reports Delivered

Lorem ipsum dolor sit amet consectetur.

“Reaching the tumour is not a logistics problem. It is a biology problem. TissueNav™ solves it at the molecular level.”

Scroll to Top